Chronic lymphocytic leukaemia vaccine - Vasogen

Drug Profile

Chronic lymphocytic leukaemia vaccine - Vasogen

Alternative Names: CLL vaccine - Vasogen; Immune modulation therapy-chronic lymphocytic leukaemia - Vasogen

Latest Information Update: 23 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vasogen
  • Class Cancer vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 23 Mar 2007 Discontinued - Phase-I for Chronic lymphocytic leukaemia in Canada (unspecified route)
  • 15 Sep 2003 A study has been added to the Cancer therapeutic trials section
  • 04 Jul 2001 Phase-I clinical trials for Chronic lymphocytic leukaemia in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top